Researchers assessed the efficacy of venetoclax-based treatments for patients with relapsed/refractory chronic lymphocytic leukemia. This study was presented at the 65th ASH Annual Meeting & Exposition...
In effort to understand the effect of the COVID-19 pandemic among patients with sickle cell disease, researchers compared outcomes and characteristics of hospitalized patients both before and during the...
In their case-controlled study that utilized the National Inpatient Sample 2016-2019 database, researchers set out to examine the relationship between leukemia and sickle cell trait.
The researchers analyzed 569 patients with multiple myeloma, stratified patients on the basis of their percentage of CD56-expressing clonal MM cells, and then evaluated patient outcomes based on this...
To examine the prognostic value of flow cytometry plus PET/CT scanning for detecting minimal residual disease in patients with multiple myeloma, researchers conducted an observational cohort study of 94...
For their study, the researchers aimed to clarify the mechanisms behind racial and ethnic disparities in multiple myeloma disease outcomes by investigating the demographic, clinical, and molecular features...
The MAIA study was a phase 3 trial comparing lenalidomide and dexamethasone alone with daratumumab as an add-on therapy to lenalidomide and dexamethasone in patients with transplant-ineligible newly...
The ANDROMEDA study was a phase 3 trial comparing bortezomib, cyclophosphamide, and dexamethasone therapy with daratumumab as an add-on therapy in patients with light chain amyloidosis.
The APOLLO study was a phase 3 trial comparing pomalidomide and dexamethasone therapy with daratumumab as an add-on therapy in patients with relapsed or refractory multiple myeloma who were refractory to...
The researchers conducted 2 studies to test the oral, small-molecule, next-generation sickle hemoglobin inhibitor would safely and substantially reduce erythrocyte hemolysis and increase hemoglobin.
